David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD. 

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical relevance of the study's findings. 

Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care? 

Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of America, to answer these questions, and to preview how the coming increase in biosimilar options might play out in a real-world landscape. 

How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patients who do not tolerate antiseptics, the benefits of visualizing antiseptics on the conjunctiva, and the specific practice patterns that work best in their clinics. 

Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, moderator John Kitchens, MD, is joined by Edwin H. Ryan, MD; Christina Y. Weng, MD, MBA; and Alison Bozung, OD, to explore why surgery for SVO has become more palatable and how this evolution in mindset is impacting patients' quality of life. 

Do the status of the fovea and/or the timing of surgery affect visual outcomes following RRD repair? Join New Retina Radio Journal Club host Lediana Goduni, MD, as she and panelists Matt Starr, MD, and Joshua Uhr, MD, dissect the findings of a recent paper exploring this question. After the break, the trio discusses tactics for overcoming challenges to real-world conditions when patients present at times when immediate surgery is not an option. 

Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.

Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care? 

Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices. 

This podcast is editorially independent, supported with advertising by Cimerli. 

The field of retina has made significant strides when it comes to diversity, equity, and inclusion since Julia A. Haller, MD, penned her inspirational 2015 JAMA Ophthalmology editorial, Cherchez la Femme. The ever-growing body of research on this topic stands as a testament to her commitment to understanding the gaps in diversity, particularly in terms of gender differences in leadership positions. Adrienne W. Scott, MD, and Steven Sanislo, MD, sit down with Dr. Haller to discuss the state of affairs in retina and just how far we have come—and how much is left to do. 

How are we doing in terms of representation on the podium? How does diversity among retina specialists affect patient care? Why is it important to look for diversity when designing an ad board or conference agenda? What drove Dr. Haller to pursue a career in a traditionally male-dominated field? Check out this episode to hear what Dr. Haller has to say.